Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Receivables (2017 - 2019)

Arcus Biosciences' quarterly Receivables came in at $62000.0 in Q2 2019, down 84.22% year-on-year from $393000.0 in Q2 2018, and down 66.12% quarter-over-quarter from $183000.0 in Q4 2018.

Arcus Biosciences has reported Receivables for 3 years, with the latest figure at $62000.0 in Q2 2019.

  • For the quarter ending Q2 2019, Receivables fell 84.22% year-over-year to $62000.0; the trailing twelve-month figure through Jun 2019 stood at $62000.0 (down 84.22% YoY), and the FY2018 full-year result was $183000.0, up 266.0% from the prior year.
  • Receivables for Q2 2019 stood at $62000.0, down from $183000.0 in the prior quarter.
  • The five-year high for Receivables was $393000.0 in Q2 2018, with the low at $50000.0 in Q4 2017.
  • Average Receivables over 3 years is $168333.3, with a median of $145500.0 recorded in 2018.
  • Year-over-year, Receivables jumped 266.0% in 2018 and slumped 84.22% in 2019.
  • Tracing RCUS's Receivables over 3 years: stood at $50000.0 in 2017, then jumped by 266.0% to $183000.0 in 2018, then sank by 66.12% to $62000.0 in 2019.
  • The last three Receivables figures came in at $62000.0 (Q2 2019), $183000.0 (Q4 2018), and $214000.0 (Q3 2018), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 13.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - 4.15 Mn
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 2.00 Bn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 5.73 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 883.96 Mn
10 Arcus Biosciences 3.18 Bn 2.36 Bn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2019 62,000.00
Dec 31, 2018 183,000.00
Sep 30, 2018 214,000.00
Jun 30, 2018 393,000.00
Mar 31, 2018 108,000.00
Dec 31, 2017 50,000.00